Carregant...
Somatic mutations of the epidermal growth factor receptor and non‐small‐cell lung cancer
Frequent overexpression of epidermal growth factor receptor (EGFR) in non‐small‐cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI‐774, Tarceva), have been developed and approved by the US Food and...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Group
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2598028/ https://ncbi.nlm.nih.gov/pubmed/17158592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmg.2006.046102 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|